THOUSAND OAKS, Calif., Aug. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food ...
Otezla (apremilast) and methotrexate are two common options for treating moderate to severe psoriasis and psoriatic arthritis, with clear differences in how they work, side effects, and how they fit ...
--Amgen today announced Otezla ® improved measures of disease severity in adults with mild-to-moderate plaque psoriasis regardless of their Body Surface Area affected by the disease, according to ...
In phase III studies, OTEZLA demonstrated clinically significant improvements across multiple manifestations of psoriatic arthritis and a consistent safety profile OTEZLA is an oral therapy that ...
The Company will be submitting the data for review to the Food and Drug Administration for inclusion in the Otezla prescribing information. Amgen announced positive topline results from the phase 3 ...
THOUSAND OAKS, Calif., May 30, 2023 /PRNewswire/ -- Amgen (AMGN) today announced new research examining the use of Otezla ® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study and ...
SUMMIT, N.J. — Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA ® (apremilast) 30 mg twice daily (BID) for the treatment of adult ...
SUMMIT, N.J.-- (BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today released new research findings on OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), ...
Amgen (NASDAQ:AMGN) today announced Otezla® (apremilast) is now available in the U.S. for pediatric use. Earlier this year, the U.S. Food and Drug Administration (FDA) approved Otezla for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results